- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Lupin and YL Biologics Receive Japanese Approval for Etanercept Biosimilar
Lupin and YL Biologics announced today that they have received approval to manufacture and sell YLB113, a biosimilar etanercept product, in Japan. The product will be Lupin’s first biosimilar to come to the Japanese market.
Lupin and YL Biologics announced today that they have received approval to manufacture and sell YLB113, a biosimilar etanercept product, in Japan. The product will be Lupin’s first biosimilar to come to the Japanese market.
Cyrus Karkaria, PhD, president of Lupin, said in a statement that “the successful filing and eventual approval of YLB113 is a major step in the fight against [autoimmune] diseases, and will allow access to an effective, affordable equivalent. After significant investment in our biotechnology [research and development] division over the years, this is the first biosimilar for regulated markets developed in-house at Lupin and the first etanercept biosimilar developed by an Indian pharmaceutical player. It is an important achievement for us that sets the tone for future biosimilar development.”
Lupin submitted its application for the etanercept biosimilar to Japanese authorities in 2018 for all indications of the reference product. The application included data from a global phase 3 clinical trial of the drug, in comparison with the reference Enbrel, conducted at 110 centers in 11 countries.
The study’s primary endpoint was equivalent improvement in rheumatoid arthritis, measured by American College of Rheumatology (ACR) criteria for 20% improvement (ACR20), at week 24. YL Biologics reported in February 2018 that the proportion of patients achieving ACR20 fell within a prespecified equivalence margin used by most advanced regulatory agencies in granting marketing authorizations. The safety and immunogenicity of YLB113 were also similar to those of the reference Enbrel.
In addition to Japan, Lupin is targeting other major regulatory territories with its biosimilar etanercept; the drug maker announced in May 2018 that it has submitted a marketing authorization application for the biosimilar to the European Medicines Agency. In 2018, Lupin said that it would submit the biosimilar for US regulatory approval in the third quarter of 2020.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
